295 related articles for article (PubMed ID: 9836589)
21. Role of annexin II tetramer in plasminogen activation.
Kang HM; Choi KS; Kassam G; Fitzpatrick SL; Kwon M; Waisman DM
Trends Cardiovasc Med; 1999; 9(3-4):92-102. PubMed ID: 10578524
[TBL] [Abstract][Full Text] [Related]
22. Ethanol-induced up-regulation of candidate plasminogen receptor annexin II in cultured human endothelial cells.
Tabengwa EM; Abou-Agag LH; Benza RL; Torres JA; Aikens ML; Booyse FM
Alcohol Clin Exp Res; 2000 Jun; 24(6):754-61. PubMed ID: 10888061
[TBL] [Abstract][Full Text] [Related]
23. Identification of annexin II heterotetramer as a plasmin reductase.
Kwon M; Caplan JF; Filipenko NR; Choi KS; Fitzpatrick SL; Zhang L; Waisman DM
J Biol Chem; 2002 Mar; 277(13):10903-11. PubMed ID: 11781322
[TBL] [Abstract][Full Text] [Related]
24. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
Stack MS; Gray RD; Pizzo SV
Cancer Res; 1993 May; 53(9):1998-2004. PubMed ID: 8481902
[TBL] [Abstract][Full Text] [Related]
25. [Mechanisms of activation of tissue-type plasminogen activator].
Fischer B
Arzneimittelforschung; 1990 May; 40(5):625-32. PubMed ID: 2116805
[TBL] [Abstract][Full Text] [Related]
26. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
27. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Kwon M; MacLeod TJ; Zhang Y; Waisman DM
Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370
[TBL] [Abstract][Full Text] [Related]
28. Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen.
Zhang X; Zhou H; Shen G; Liu Z; Hu Y; Wei W; Song S
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):21-3, 76. PubMed ID: 12658774
[TBL] [Abstract][Full Text] [Related]
29. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid.
Muldowney JA; Painter CA; Sanders-Bush E; Brown NJ; Vaughan DE
Thromb Haemost; 2007 Feb; 97(2):263-71. PubMed ID: 17264956
[TBL] [Abstract][Full Text] [Related]
30. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of plasmin generation by S100A10.
Miller VA; Madureira PA; Kamaludin AA; Komar J; Sharma V; Sahni G; Thelwell C; Longstaff C; Waisman DM
Thromb Haemost; 2017 Jun; 117(6):1058-1071. PubMed ID: 28382372
[TBL] [Abstract][Full Text] [Related]
32. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
33. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
34. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering.
Gundersen D; Trân-Thang C; Sordat B; Mourali F; Rüegg C
J Immunol; 1997 Feb; 158(3):1051-60. PubMed ID: 9013942
[TBL] [Abstract][Full Text] [Related]
35. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen binds to plasmin-modulated factor Xa by Ca(2+) - and C-terminal lysine-dependent and -independent interactions.
Grundy JE; Hancock MA; Meixner SC; MacKenzie RC; Koschinsky ML; Pryzdial EL
Thromb Haemost; 2007 Jan; 97(1):38-44. PubMed ID: 17200769
[TBL] [Abstract][Full Text] [Related]
37. The role of the annexin A2 heterotetramer in vascular fibrinolysis.
Madureira PA; Surette AP; Phipps KD; Taboski MA; Miller VA; Waisman DM
Blood; 2011 Nov; 118(18):4789-97. PubMed ID: 21908427
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
39. Herpesviruses enhance fibrin clot lysis.
Gershom ES; Vanden Hoek AL; Meixner SC; Sutherland MR; Pryzdial EL
Thromb Haemost; 2012 Apr; 107(4):760-8. PubMed ID: 22318336
[TBL] [Abstract][Full Text] [Related]
40. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
